Compounded GLP-1 Telehealth Saturday Market Sentiment: Ozari Health $86/Month Floor Holds, FDA 503B Comment Window Closes June 29
Six weeks ahead of the FDA's June 29 closing date for public comments on the April 30 503B bulks-list proposal excluding semaglutide, tirzepatide, and liraglutide, the compounded-GLP-1 telehealth segment has settled into a defensive pricing structure. Ozari Health's May 19 launch at $86/month compounded semaglutide and $120/month compounded tirzepatide established the floor; comparable platforms have held prices steady at $99-249/month rather than competing further on price. The Saturday market sentiment is split: bull case is that the FDA's final determination could grandfather existing 503A patients under a transition window, leaving cash-pay compounded GLP-1 viable through 2027; bear case is that the BSR Intelligence-documented 90% YoY drop in compounded semaglutide shipments accelerates as 503B compounding ends, with only the smallest-volume 503A pharmacies remaining. Patient migration toward branded Wegovy via Novo's Hims & Hers branded-distribution channel (125K shipments in six weeks) is the natural off-ramp.